Avigitx is developing a disease‑modifying therapy for chronic kidney disease that precisely inhibits the upstream enzymes driving renal tissue degradation. By targeting these molecular mechanisms, the treatment aims to halt or reverse kidney function decline, extending the time patients can spend outside of medical care.
Funding
$383.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic kidney disease progresses due to enzymatic pathways that degrade renal function, and existing treatments address symptoms rather than the underlying molecular causes, leading to continued loss of kidney function and reduced patient lifespan.
Solution
Avigitx is developing a novel therapeutic approach that precisely targets the upstream enzymes responsible for renal tissue degradation. By inhibiting these specific biological mechanisms, the therapy aims to halt or reverse kidney function decline, preserving organ health. The platform leverages cutting‑edge molecular biology and drug discovery techniques to create agents that act where conventional modalities cannot. Clinical development is structured to bring the therapy to patients with progressive kidney disease as efficiently as possible, with the ultimate goal of extending the time patients can spend outside of medical care.
Target Audience
Primary customers are patients with chronic kidney disease and healthcare providers seeking disease‑modifying therapies, as well as pharmaceutical partners interested in co‑development or licensing of the technology.
Features
- Precision targeting of key renal‑destructive enzymes identified through advanced molecular profiling
- Novel mechanism of action distinct from existing symptomatic treatments for kidney disease
- Utilization of state‑of‑the‑art drug discovery and preclinical validation pipelines
- Focus on disease‑modifying outcomes to preserve kidney function and delay progression
- Integrated patient‑centric development strategy to align clinical endpoints with quality‑of‑life improvements